AiCuris

Based in Germany, AiCuris Anti-infective Cures focuses on developing innovative antiviral therapies for patients with compromised immune systems, particularly targeting infections from the herpes simplex virus. AiCuris Anti-infective Cures AG, founded in 2006 in Wuppertal, Germany, is dedicated to developing antiviral treatments. In February 2026, Asahi Kasei Corporation, a portfolio company of Veloxis Pharmaceuticals A/S agreed to fully acquire AiCuris from Athos Service for EUR 780 million in an all cash transaction. The company engages in one deal, marking a strategic move in the antiviral space.

AiCuris specializes in the development of antiviral therapies, focusing on patients with weakened immune systems. Its notable products, Pritelivir and AIC468, are aimed at treating herpes simplex virus infections in immunocompromised individuals. Pritelivir is currently undergoing various phases of clinical trials, showing efficacy against refractory HSV in patients with HIV. AiCuris serves a global market, including healthcare providers and research institutions, particularly in Europe and North America.

AiCuris generates revenue through partnerships with healthcare providers and institutions for the development and distribution of its antiviral products. The pricing structure is contingent on agreements with clinical settings where Pritelivir and AIC468 are administered during trials or post-approval, aiming to provide effective antiviral solutions to vulnerable patient populations. The Februaru 2026 Acquisition will enable Asahi Kasei Corporation to expand its portfolio of therapies for severe viral infections in immunocompromised patients by integrating Aicuris’ late‑stage antiviral candidates and established transplant‑center network.